articleTop 1% cited
CALR vs JAK2 vs MPL-mutated or triple-negative myelofibrosis: clinical, cytogenetic and molecular comparisons
Leukemia · 2014 · Vol. 28(7) · pp. 1472–1477
Ayalew Tefferi✉(Mayo Clinic in Arizona)Terra L. Lasho(Mayo Clinic in Arizona)Christy M. Finke(Mayo Clinic in Arizona)Ryan A. Knudson(Mayo Clinic in Arizona)Rhett P. Ketterling(Mayo Clinic in Arizona)Chris Hanson(Mayo Clinic)Margherita Maffioli(Ospedale di Circolo e Fondazione Macchi)Domenica Caramazza(Ospedale di Circolo e Fondazione Macchi)Francesco Passamonti(Ospedale di Circolo e Fondazione Macchi)Animesh Pardanani(Mayo Clinic in Arizona)
Myeloproliferative Neoplasms: Diagnosis and TreatmentChronic Myeloid Leukemia TreatmentsKruppel-like factors researchMyelofibrosisCalreticulinEssential thrombocythemiaInternal medicineLeukocytosisUnivariate analysisMedicinePolycythemia veraMutationGastroenterology
MeSH terms
AgedAged, 80 and overChromosome AberrationsDNA Mutational AnalysisFemaleHumansMaleMiddle AgedMutationPrognosisGene ExpressionCalreticulinJanus Kinase 2Receptors, ThrombopoietinPrimary Myelofibrosis
Citations
536
FWCI
43.09
field-weighted impact
References
33
Percentile
100%
vs. same field & year
Citations per year
References
Calreticulin exposure dictates the immunogenicity of cancer cell death
Nature Medicine · 2006 · 3,040 citations
Mutations and prognosis in primary myelofibrosis
Leukemia · 2013 · 741 citations
Citation Network
How this paper connects to the literature. Drag to explore, click any node to open that paper.